Skip to main content

Drug Interactions between omadacycline and Sohonos

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

omadacycline palovarotene

Applies to: omadacycline and Sohonos (palovarotene)

CONTRAINDICATED: Concomitant use of systemic vitamin A derivatives (e.g., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign intracranial hypertension. These agents have each been individually associated with the development of pseudotumor cerebri and may have additive effects if administered concurrently. This interaction has been suspected in reported cases involving the use of some retinoids (e.g., isotretinoin) in combination with a tetracycline.

MANAGEMENT: Coadministration of most systemic vitamin A derivatives with tetracyclines is considered contraindicated. One publication recommends a drug-free period, or washout, between the two medications. The authors suggest a 7-day washout period if the patient has normal renal and liver function, is using the tetracycline for acne, and is changing from a tetracycline to a vitamin A derivative. All patients should be counseled to contact their healthcare provider immediately if they develop signs or symptoms of pseudotumor cerebri such as papilledema, headache, nausea, vomiting, and/or visual disturbances. The patient should be advised to discontinue the retinoid and tetracycline antibiotic and be referred for immediate neurological evaluation and care if pseudotumor cerebri is suspected as this could result in permanent vision loss.

References (27)
  1. Walters BN, Gubbay SS (1981) "Tetracycline and benign intracranial hypertension: report of five cases." Br Med J, 282, p. 19-20
  2. Minutello JS, Dimayuga RG, Carter J (1988) "Pseudotumor cerebri, a rare adverse reaction to tetracycline therapy." J Periodontol, 59, p. 848-51
  3. Delaney RA, Narayanaswamy TR (1990) "Pseudo-tumor cerebri and acne." Mil Med, 155, p. 511
  4. Donnet A, Dufour H, Graziani N, Grisoli F (1992) "Minocycline and benign intracranial hypertension." Biomed Pharmacother, 46, p. 171-2
  5. (2001) "Product Information. Achromycin (tetracycline)." Lederle Laboratories
  6. Yokokura M, Hatake K, Komatsu N, Kajitani H, Miura Y (1994) "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet, 343, p. 361-2
  7. Schmitt K, Schwarz R, Tulzer G, Krieger O, Zoubek A, Gadner H (1994) "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet, 343, p. 361
  8. Gardner K, Cox T, Digre KB (1995) "Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review." Neurology, 45, p. 6-10
  9. Cuddihy J (1994) "Case report of benign intercranial hypertension secondary to tetracycline." Ir Med J, 87, p. 90
  10. Lee AG (1995) "Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne." Cutis, 55, p. 165-8
  11. Roytman M, Frumkin A, Bohn TG (1988) "Pseudotumor cerebri caused by isotretinoin." Cutis, 42, p. 399-400
  12. Lewis PA, Kearney PJ (1997) "Pseudotumor cerebri induced by minocycline treatment for acne vulgaris." Acta Derm Venereol, 77, p. 83
  13. Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, Musson KH, Eggenberger ER (1998) "Minocycline treatment and pseudotumor cerebri syndrome." Am J Ophthalmol, 126, p. 116-21
  14. Weese-Mayer DE, Yang RJ, Mayer JR, Zaparackas Z (2001) "Minocycline and Pseudotumor cerebri: The well-known but well-kept secret." Pediatrics, 108, p. 519-20
  15. Moskowitz Y, Leibowitz E, Ronen M, Aviel E (1993) "Pseudotumor cerebri induced by vitamin A combined with minocycline." Ann Ophthalmol, 25, p. 306-8
  16. Chan AY, Liu DT, Friedman DI, Gordon LK, Egan RA (2005) "Doxycycline and intracranial hypertension." Neurology, 64, p. 765-6
  17. Tabibian JH, Gutierrez MA (2009) "Doxycycline-induced pseudotumor cerebri." South Med J, 102, p. 310-1
  18. (2018) "Product Information. Seysara (sarecycline)." Allergan Inc
  19. (2022) "Product Information. Sohonos (palovarotene)." Ipsen Biopharmaceuticals Canada inc, 1
  20. Gasparian S, Geng X, Hawy E (2021) "Intracranial hypertension associated with topical tretinoin use." Am J Ophthalmol Case Rep, 23, p. 101130
  21. Caruana DM, Wylie G (2023) 'Washout' period for oral tetracycline antibiotics prior to systemic isotretinoin. https://academic.oup.com/bjd/article-abstract/174/4/929/6617935?redirectedFrom=fulltext&login=false
  22. (2023) "Product Information. Neotigason (acitretin)." Teva UK Ltd
  23. (2022) "Product Information. Acitretin (acitretin)." AvKare Inc
  24. (2023) "Product Information. Alitretinoin (alitretinoin)." Ennogen Healthcare Ltd
  25. (2022) "Product Information. Isotretinoin (isotretinoin)." Sun Pharmaceutical Industries Europe B.V.
  26. (2022) "Product Information. Absorica LD (ISOtretinoin)." Sun Pharmaceutical Industries
  27. (2023) "Product Information. Tretinoin (tretinoin)." Neon Healthcare Ltd

Drug and food interactions

Major

palovarotene food

Applies to: Sohonos (palovarotene)

GENERALLY AVOID: Grapefruit, pomelo, grapefruit hybrids, and juices or supplements containing these fruits may increase the plasma concentrations of palovarotene. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in these fruits. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with these fruits. Concomitant use of erythromycin, a moderate CYP450 3A4 inhibitor, with palovarotene at steady-state plasma levels increased its peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.6 and 2.5-fold, respectively. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased concentrations of palovarotene may increase the risk of adverse effects such as dry skin, dry lips, alopecia, pruritus, erythema, paronychia, cellulitis, decubitus ulcer, xerophthalmia, night blindness, depression, mood alterations, and pseudotumour cerebri (benign intracranial hypertension).

ADJUST DOSE: Food increases oral absorption of palovarotene.

MANAGEMENT: The manufacturer advises that concomitant use of palovarotene with grapefruit, pomelo, grapefruit hybrids and juices or supplements containing these fruits should be avoided. To ensure maximal absorption, palovarotene should be administered with food.

References (2)
  1. (2022) "Product Information. Sohonos (palovarotene)." Ipsen Biopharmaceuticals Canada inc, 1
  2. (2023) "Product Information. Sohonos (palovarotene)." Ipsen Biopharmaceuticals, Inc
Moderate

omadacycline food

Applies to: omadacycline

ADJUST DOSING INTERVAL: Administration with food, particularly dairy products, may reduce the absorption of omadacycline. The calcium content of these foods may form nonabsorbable chelates with omadacycline.

MANAGEMENT: Omadacycline should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.

References (1)
  1. (2018) "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer